Can a new drug calm gut inflammation without the skin side effects?
NCT ID NCT07529236
First seen Apr 15, 2026 · Last updated May 22, 2026 · Updated 5 times
Summary
This study follows 40 children with Crohn's disease or ulcerative colitis who developed severe psoriasis from anti-TNF drugs and switched to ustekinumab. Researchers want to see if their gut disease stays under control 3 to 6 months after the switch. The goal is to find a treatment that works for both the gut and the skin.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CHRONIC INFLAMMATORY BOWEL DISEASES are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
CHU de Nice
Nice, France, 06000, France
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Contact
Conditions
Explore the condition pages connected to this study.